Improvement and clinical benefit analysis of low-dose ketamine on postoperative pain and sleep after sinus surgery

Abstract

Objective To investigate the benefits of low-dose esketamine on pain relief and sleep quality improvement after sinus surgery. Methods One hundred and thirty-five patients admitted to our hospital between June 2018 and September 2023 who suffered from sinusitis and were scheduled to undergo functional endoscopic sinus surgery were recruited. Three groups were divided as 0.2 mg (n = 45), 0.3 mg (n = 45), and control (n = 45) using a random number table. Three groups were tested for the Pittsburgh Sleep Quality Index (PSQI), the Visual Analogue Scale (VAS), the Hamilton Depression Scale (HAMD), the Hamilton Anxiety Scale (HAMA), the Connor-Davidson Resilience Scale (CD-RISC), and the Sino-nasal Outcome Test-20 (SNOT-20), and the related scores were analyzed by comparing their means between the groups. Results Esketamine affected differently the PSQI, the VAS, the HAMD, the HAMA, the CD-RISC, and the SNOT-20 scores in patients (FPSQI score treatment=67.569 FHAMD score treatment=59.593, FHAMA score treatment=71.479, FCD−RISC score treatment=65.549, F SNOT−20 score treatment=66.429, FVAS score treatment=56.73, all P < 0.05). The PSQI, the HAMD, the HAMA, the SNOT-20, and the VAS scores were in the same order at the four-time points of 1, 3, 5, and 9 days ( the order at all four-time points was: control > 0.2 mg > 0.3 mg), while the order of the CD-RISC scores at the four-time points was: control < 0.2 mg < 0.3 mg. Conclusion Low-dose esketamine boasts relief of postoperative anxiety, pain, and depression, reduction of patient symptoms, and improvement of sleep quality after sinus surgery.